TR
EN
Acute phase reaction with zoledronic acid infusion mimicking COVID-19
Abstract
During the pandemic, symptoms of many diseases that can be confused with the symptoms of COVID-19 have been detected and reported. In this case report, we reported a patient who showed flu-like symptoms and sudden lymphopenia within two days of zoledronic acid infusion. A 40-year-old female patient with a COVID-19 history was admitted to our hospital with abdominal pain. Hypercalcemia due to parathyroid adenoma was detected. Zoledronic acid (5 mg) was given intravenously for the treatment of hypercalcemia. Following the infusion, fever, C-Reactive Protein (CRP) increase and lymphopenia were detected in the patient. There were no apparent causes to explain these symptoms. The side effects we detected in the patient were confusingly similar to the symptoms of COVID-19. Repeated PCR tests and CT results indicated that the patient did not have COVID-19. A week later, the patient’s symptoms improved and the laboratory findings along with the physical examination returned to normal. The patient's condition was considered to be due to zoledronic acid infusion. We would like to draw attention to the acute phase reaction after zoledronic acid infusion in the COVID-19 era in which the clinical situation could be confusing.
Keywords
Kaynakça
- Leere JS, Karmisholt J, Robaczyk M, Vestergaard P. Contemporary Medical Management of Primary Hyperparathyroidism: A Systematic Review. Front Endocrinol (Lausanne). 2017 Apr 20;8.
- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020 Feb;395(10223):497–506.
- Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, Villamizar-Peña R, Holguin-Rivera Y, Escalera-Antezana JP, et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis. 2020 Mar;34:101623.
- Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. 2020 Mar; 395(10229):1054–62.
- Coleman R, Burkinshaw R, Winter M, Neville-Webbe H, Lester J, Woodward E, et al. Zoledronic acid. Expert Opin Drug Saf. 2011 Jan 29;10(1):133–45.
- Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis. New England Journal of Medicine. 2007 May 3;356(18):1809– 22.
- Boonen S, Black DM, Colón-Emeric CS, Eastell R, Magaziner JS, Eriksen EF, et al. Efficacy and Safety of a Once-Yearly Intravenous Zoledronic Acid 5 mg for Fracture Prevention in Elderly Postmenopausal Women with Osteoporosis Aged 75 and Older. J Am Geriatr Soc. 2010 Feb;58(2):292–9.
- Schweitzer DH, Oostendorp-van de Ruit M, van der Pluijm G, Löwik CWGM, Papapoulos SE. Interleukin-6 and the acute phase response during treatment of patients with paget’s disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate. Journal of Bone and Mineral Research. 2009 Dec 3;10(6):956–62.
Ayrıntılar
Birincil Dil
İngilizce
Konular
Endokrinoloji
Bölüm
Olgu Sunumu
Yayımlanma Tarihi
18 Eylül 2023
Gönderilme Tarihi
4 Ekim 2022
Kabul Tarihi
26 Nisan 2023
Yayımlandığı Sayı
Yıl 2023 Cilt: 62 Sayı: 3